Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GABLE: Adjuvant Therapy Assignment in Gastric Cancer
NCT03515941Phase 1Terminated
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of oxaliplatin, capecitabine and fluorouracil in gastric adenocarcinoma (2 arms). Primary endpoint: Number of Participants Who Complete the Recommended Therapy at 17 weeks. Started Jun 2018; status: terminated.
02
Drugs
oxaliplatincapecitabinefluorouracil
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03515941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515941.